uniQure N.V. (QURE) Current Ratio
- Current ratio · latest quarter: Value 10.40×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 10.40× | Current assets / current liabilities. $615.74M ÷ $59.20M ≈ 10.40× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 615.74M USD | Assets, Current |
| Current obligations | 59.20M USD | Liabilities, Current |
| Cash and equivalents | 139.99M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 3.56M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | Inventory, Net |
| Payables | 4.40M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | $615.74M | $59.20M | $139.99M | (m) | $3.56M | (m) | $4.40M | (m) | 10.40× |
| 2025-12-31 | $655.99M | $62.92M | $80.24M | (m) | $5.86M | (m) | $5.17M | (m) | 10.43× |
| 2025-09-30 | $716.19M | $100.63M | $597.06M | (m) | (m) | (m) | $6.23M | (m) | 7.12× |
| 2025-06-30 | $408.57M | $40.93M | $253.78M | (m) | (m) | (m) | $5.54M | (m) | 9.98× |
| 2025-03-31 | $435.42M | $36.31M | $217.23M | (m) | (m) | (m) | $5.27M | (m) | 11.99× |
| 2024-12-31 | $390.29M | $40.05M | $158.93M | (m) | (m) | (m) | $7.23M | (m) | 9.74× |
| 2024-09-30 | $464.14M | $71.27M | $251.63M | (m) | (m) | (m) | $5.44M | (m) | 6.51× |
| 2024-06-30 | $591.97M | $80.47M | $287.88M | (m) | (m) | (m) | $4.41M | (m) | 7.36× |
| 2024-03-31 | $596.00M | $63.47M | $243.06M | (m) | (m) | $7.67M | $5.23M | (m) | 9.39× |
| 2023-12-31 | $651.85M | $73.67M | $241.36M | (m) | (m) | $12.02M | $6.59M | (m) | 8.85× |
| 2023-09-30 | $693.63M | $68.61M | $229.48M | (m) | (m) | $15.65M | $5.58M | (m) | 10.11× |
| 2023-06-30 | $756.96M | $68.36M | $513.60M | (m) | (m) | $10.21M | $9.37M | (m) | 11.07× |
| 2023-03-31 | $442.64M | $66.34M | $153.85M | (m) | (m) | $7.48M | $8.88M | (m) | 6.67× |
| 2022-12-31 | $476.77M | $75.92M | $228.01M | (m) | (m) | $6.92M | $10.98M | (m) | 6.28× |
| 2022-09-30 | $464.58M | $63.97M | $440.31M | (m) | (m) | $4.08M | $7.57M | (m) | 7.26× |
| 2022-06-30 | $523.30M | $48.26M | $500.52M | (m) | (m) | $2.95M | $10.03M | (m) | 10.84× |
| 2022-03-31 | $578.21M | $44.70M | $524.89M | (m) | (m) | (m) | $9.92M | (m) | 12.94× |
| 2021-12-31 | $628.24M | $36.76M | $556.26M | (m) | (m) | (m) | $2.50M | (m) | 17.09× |
| 2021-09-30 | $593.76M | $41.92M | $578.46M | (m) | $3.77M | (m) | $5.37M | (m) | 14.17× |
| 2021-06-30 | $694.22M | $46.09M | $677.33M | (m) | $2.71M | (m) | $16.82M | (m) | 15.06× |
| 2021-03-31 | $282.33M | $32.10M | $260.81M | (m) | $5.45M | (m) | $5.75M | (m) | 8.79× |
| 2020-12-31 | $258.91M | $27.33M | $244.93M | (m) | (m) | (m) | $3.77M | (m) | 9.47× |
| 2020-09-30 | $287.38M | $33.35M | $279.49M | (m) | (m) | (m) | $2.35M | (m) | 8.62× |
| 2020-06-30 | $319.63M | $29.84M | $314.26M | (m) | (m) | (m) | $4.94M | (m) | 10.71× |
| 2020-03-31 | $349.60M | $27.13M | $342.03M | (m) | (m) | (m) | $4.99M | (m) | 12.89× |
| 2019-12-31 | $384.21M | $31.63M | $377.79M | (m) | (m) | (m) | $5.68M | (m) | 12.15× |
| 2019-09-30 | $407.64M | $28.45M | $403.16M | (m) | (m) | (m) | $3.78M | (m) | 14.33× |
| 2019-06-30 | $188.54M | $23.37M | $184.09M | (m) | (m) | (m) | $4.52M | (m) | 8.07× |
| 2019-03-31 | $213.19M | $22.42M | $208.79M | (m) | (m) | (m) | $3.53M | (m) | 9.51× |
| 2018-12-31 | $236.58M | $19.97M | $234.90M | (m) | (m) | (m) | $3.79M | (m) | 11.85× |
| 2018-09-30 | $242.08M | $32.01M | $239.55M | (m) | (m) | (m) | $4.12M | $11.11M | 7.56× |
| 2018-06-30 | $262.71M | $31.44M | $259.18M | (m) | (m) | (m) | $3.87M | $8.03M | 8.36× |
| 2018-03-31 | $145.47M | $26.56M | $140.82M | (m) | (m) | (m) | $3.69M | $4.44M | 5.48× |
| 2017-12-31 | $162.78M | $19.23M | $159.37M | (m) | (m) | (m) | $2.91M | $1.05M | 8.47× |
| 2017-09-30 | $92.31M | $25.37M | $88.93M | (m) | (m) | (m) | $2.99M | $6.23M | 3.64× |
| 2017-06-30 | $111.42M | $23.13M | $104.09M | (m) | $4.19M | (m) | $3.46M | $4.32M | 4.82× |
| 2017-03-31 | $123.73M | $20.47M | $120.27M | (m) | $1.23M | (m) | $3.95M | $2.44M | 6.04× |
| 2016-12-31 | $143.95M | $22.72M | $132.50M | (m) | $3.68M | (m) | $5.52M | $605.00K | 6.34× |
| 2015-12-31 | $228.11M | $26.91M | $221.63M | (m) | (m) | $474.00K | $4.06M | $5.58M | 8.48× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |